

**Thomas A. Wolf, M.D.**  
Cognitive Clinical Trials Research  
8901 E. Pima Center Parkway, Suite 115  
Scottsdale, AZ 85258

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

**AFFILIATIONS:**

Prairie Fields Family Medicine  
350 W. 23<sup>rd</sup> Street A  
Fremont, NE 68025

Heritage Ridge/CCT  
1502 Fort Crook Road S  
Bellevue, NE 68005

The Heritage at Sterling Ridge/CCT  
1111 Sterling Ridge Drive  
Omaha, NE 68144

Heritage Pointe/CCT  
16811 Burdette Street  
Omaha, NE 68116

**EDUCATION:**

2002 Internal Medicine Clinical Elective in El Salvador

2001 Rural Family Medicine Clinical Elective

1998 - 2002 M.D.  
University of Nebraska Medical Center, Omaha, NE

1993 - 1997 B.S. in Biology  
University of Nebraska, Lincoln, NE

**RESIDENCY:**

2002 - 2005 Residency, Via Christi Family Practice Program  
Wichita Center for Graduate Medical Education, Wichita, KS

**CERTIFICATIONS AND LICENSURE:**

2006 - Present	Nebraska Medical License (23824)
2005 - Present	American Board of Family Practice
2005 - Present	Basic Cardiac Life Support
2005 - Present	Advanced Cardiac Life Support
2004 - Present	Pediatric Advanced Life Support
2004 - Present	Neonatal Resuscitation Program
2002 - 2011	Advanced Life Support in Obstetrics
Jan 2000	USMLE Step I
Jan 2002	USMLE Step II
Apr 2003	USMLE Step III
May 2003	Advanced Trauma Life Support

**PROFESSIONAL SOCIETY MEMBERSHIPS:**

2007 - Present	American Association for Primary care and Endoscopy
2006 - Present	Nebraska Academy of Family Physicians
2002 – 2006	Kansas Academy of Family Physicians
1998 – Present	American Medical Association
1998 – Present	American Academy of Family Physicians
1998 – 2002	American Medical Student Association

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, 2019 – Present  
Cognitive Clinical Trials Research, Fremont, NE

*Principal Investigator*, 2011 – 2019  
Synexus Clinical Research US, Inc., Fremont, NE

*Physician*, 2006 - Present  
Prairie Fields Family Medicine, LLC., Fremont, NE

*Volunteer Faculty*, 2008 - Present  
University of Nebraska Medical Center, Omaha, NE

*Full Endoscopy Privileges*, 2007 - Present  
Methodist Fremont Health Surgical Center, Fremont, NE

**PROFESSIONAL EXPERIENCE (*continued*):**

***Full Staff Privileges including Endoscopy***, 2006 - Present  
Methodist Fremont Health, Fremont, NE

***Hospitalist Physician***, 2005 – 2006  
Kansas Inpatient Services, Wichita, KS

***Volunteer Faculty***, 2005 - 2006  
KUMC- Wichita, Wichita, KS

***Pharmacy Technician***, 1997 – 1998  
Bryan LGH Memorial Hospital, Lincoln, NE

**INVESTIGATOR EXPERIENCE:**

Allergy • Cardiovascular • Common Cold • COPD • Device • Diabetes • Influenza • Migraine  
Opioid-Induced Constipation • Osteoarthritis • Pain • Post-Herpetic Neuralgia • Vaccine

**INVESTIGATOR EXPERIENCE:**

***Allergy***

An optional prospective follow-on study to evaluate the continued efficacy and safety of XXX in cat allergic subjects up to five years after the administration of treatment.

***Cardiovascular***

A 52-week, phase III double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of XXX in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events

A XXX Cardiovascular morbidity and mortality (ACCLAIM) study in subjects with documented Cardiovascular disease.

***Common Cold***

A randomized, parallel-group, placebo-controlled, double-blind study to evaluate the efficacy and safety of XXX Nasal Spray in adult subjects with symptoms of common cold.

***COPD***

A Pilot Study in COPD and asthmatic patients to ascertain patient acceptability/suitability and technological feasibility of data collection by remote monitoring devices.

**INVESTIGATOR EXPERIENCE (*continued*):**

A Pilot Study in COPD and asthmatic patients to ascertain patient acceptability/suitability and technological feasibility of data collection by remote monitoring devices

A 24 week treatment, multicenter, randomized, double-blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of XXX/ XXX, XXX dose combination XXX compared with each monotherapy (XXX and XXX) and XXX when administered to patients with stable chronic obstructive pulmonary disease.

Double-blind, randomization, placebo-controlled, parallel-group, phase IV study to evaluate the effect of XXX on Long-term Cardiovascular Safety and COPD exacerbations in patients with Moderate to Very Severe COPD.

A 12-week multicenter, randomization, double-blind, placebo-controlled study to assess the efficacy and safety of XXX in stable COPD patients.

***Diabetes***

A trial comparing the efficacy and safety of insulin XXX and insulin XXX XXX in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs.

Efficacy in controlling glycaemia with XXX as add-on to metformin vs. XXX as add-on to XXX after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with XXX monotherapy and treated in a primary care setting.

A real world, point-of-care, randomized, parallel group, open, 6-month clinical study to evaluate the effect of a digital disease management tool in patients with type 2 diabetes mellitus.

Six-month, Randomized, open-label, parallel-group comparison of the insulin XXX to XXX in adult patients with Type 2 Diabetes Mellitus also using Insulin XXX.

A trial comparing cardiovascular safety and insulin XXX versus XXX in subjects with type 2 diabetes at high risk of cardiovascular events.

***Influenza***

Performance Evaluation of the XXX Device Test with Lay Users Self-Testing

A randomized, double-blind, Phase II study comparing the efficacy, safety and tolerability of combination antivirals (XXX, XXX, XXX) versus XXX for the treatment of influenza in Adults at risk for complications.

**INVESTIGATOR EXPERIENCE (continued):**

A randomized double-blind, phase 2 study comparing the efficacy, safety and tolerability of combination antivirals (XXX, XXX, XXX) versus XXX for the treatment of Influenza in Adults at risk for complication.

A randomization, double-blind, phase 2 study comparing the efficacy, safety and tolerability of combination antivirals XXX versus XXX for the treatment of Influenza in Adults at Risk for Complication.

A randomization, double-blind study comparing XXX versus Placebo for the treatment of Influenza in Low Risk Adults.

***Migraine***

A multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of XXX in the acute treatment of migraine with or without aura.

A phase III, multicenter, randomized, double-blind, placebo controlled single attack study to evaluate the efficacy, safety and tolerability of XXX in the acute treatment of migraine.

A multicenter, randomized, double-blind, parallel-group study evaluating the long-term safety and tolerability, and efficacy of Subcutaneous Administration of XXX for the preventative treatment of Migraine.

A multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing the efficacy and safety of XXX regimens of subcutaneous administration of XXX versus placebo for the preventative treatment of Episodic Migraine.

A multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing the efficacy and safety of 2 dose regimens of Subcutaneous Administration of XXX versus Placebo for the preventative treatment of Chronic Migraine.

An Open-Label long term safety study of XXX in the Acute treatment of Migraine.

A study of two doses of XXX compared to placebo in the acute treatment of Migraine: A randomized, double-blind, placebo-controlled parallel group study.

***Osteoarthritis***

A phase III randomized, multi-dose, placebo-controlled, double-blind study to evaluate the long-term efficacy and safety of XXX in patients with pain due to osteoarthritis of the knee or hip.

A randomized, double-blind, parallel-group study of cardiovascular safety in Osteoarthritis or Rheumatoid Arthritis patients with or at high risk of cardiovascular disease comparing XXX with XXX and XXX.

**INVESTIGATOR EXPERIENCE (*continued*):**

***Pain***

A multicenter, randomized, double-blind, parallel-group, comparative study of XXX vs. XXX for the prevention of Post-Herpetic Neuralgia and treatment of Acute Herpes Zoster-Associated Pain.

A randomization Double-Blind, Placebo-controlled, parallel-group, multicenter, Phase III study to evaluate the long-term safety of XXX for the treatment of Opioid-induced constipation in Subjects with Nonmalignant Chronic Pain receiving Opioid Therapy.

***Vaccine***

A Phase III, randomized, active-controlled, observer-blinded study assess the immunogenicity, safety, and tolerability of XXX when administered as a XXX regimen and a first-in-human study to describe the immunogenicity, safety and tolerability of a XXX vaccine (XXX) in healthy subjects 10 to <26 years of age.

A duration-of-immunity study to assess persistence of hSBA response for up to 48 months after completion of vaccination with XXX.

A phase III, observer-blind, randomization, controlled, multicenter study to evaluate the safety of a XXX Vaccine produced either in mammalian cell culture or in Embryonated Chicken Eggs XXX, in healthy children and adolescents 4 to 17 years of age.

***Other Indications***

A multicenter study conducted to evaluate the performance of the XXX test in laboratory and point of care testing sites.

A phase III, observer-blinded, randomization, active-controlled XXX, multicenter trials of the safety and immunogenicity of XXX adults 18 to 70 years of age.

Outcomes registry for better informed treatment of Atrial Fibrillation II.

**ADDITIONAL RESEARCH EXPERIENCE:**

1999 Research Assistant for Dr. Carol Toris performing experiments measuring aqueous humor production in patients with both normal and elevated intraocular pressures.

1998 Research Assistant to Dr. Tyler Kokjohn in the Department of Microbiology. My projects involved the study of DNA repair mechanisms

1996 Research Assistant to Dr. Richard Legge in which we analyzed case reports and then presented them in March of 1997 at UNMC's annual Ophthalmology conference.